The Phase 3 study (NCT06045221) investigating orforglipron in participants with Type 2 diabetes reached primary completion on 2025-08-22. This trial compared orforglipron with oral semaglutide in 1698 participants whose Type 2 diabetes was inadequately controlled with metformin.
Background
The study, titled "A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin," aimed to assess the efficacy and safety of orforglipron as a treatment for Type 2 diabetes.
Trial design
The study (NCT06045221) was a Phase 3 trial that enrolled 1698 participants with Type 2 diabetes. The trial's main purpose was to assess the efficacy and safety of orforglipron compared with oral semaglutide. Participants had Type 2 diabetes that was inadequately controlled with metformin. The study duration was approximately 61 weeks.
What this means
The primary completion of this Phase 3 trial indicates that data collection for the study's main objectives has concluded. The trial's findings, once released, will provide crucial information on the comparative efficacy and safety of orforglipron against oral semaglutide for individuals with Type 2 diabetes inadequately controlled by metformin. These results are anticipated to inform future treatment decisions and the potential role of orforglipron in diabetes management.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06045221, titled "A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin," was updated on 2025-08-22 on clinicaltrials.gov.